Psychedelic-Assisted Therapy Speaker Series

The Brown School and Professional Development are proud to announce the launch of a new, essential Psychedelic-Assisted Therapy Speaker Series.

Collaborating with the Center for Holistic Interdisciplinary Research in Psychedelics (CHIRP) and the Kathryn M. Buder Center for American Indian Studies, this monthly, lunchtime series brings together leading experts to explore the latest science, legal landscapes, Indigenous perspectives, and clinical applications of psychedelics in a therapeutic context. Attendees will gain critical insights into this rapidly evolving field, ensuring they are at the forefront of the mental health revolution.

Psychedelics in Mental Health Treatment: Hope or Hype?
January 13, 2026 | 12:00 Noon – 1:30 p.m., Central Time Zone

Indigenous Perspectives on Psychedelics
February 10, 2026 | 12:00 Noon – 1:30 p.m., Central Time Zone

Understanding the Legal and Regulatory Landscape of Psychedelics in the US
March 3, 2026 | 12:00 Noon – 1:30 p.m., Central Time Zone

Rewiring Resilience: Ketamine-Assisted Psychotherapy for Dual-Diagnosis Trauma and Addiction
April 7, 2026 | 12:00 Noon – 1:30 p.m., Central Time Zone

Supporting Clients in Psychedelic Use: A Harm-Reduction Framework
May 12, 2026 | 12:00 Noon – 1:30 p.m., Central Time Zone

This learning experience is designed to:

  1. Expand Knowledge – Offer an accessible, evidence-informed introduction to essential concepts, history, safety considerations, and therapeutic frameworks in PAT for students and practicing professionals.
  2. Bridge Research and Practice – Translate current scientific findings into practical, ethical, and culturally responsive approaches that can guide real-world clinical decision-making.
  3. Foster Workforce Readiness – Build foundational competencies aligned with insights from our multi-state workforce assessment, emphasizing trauma-informed, person-centered, and equity-focused care.
  4. Promote Cross-Disciplinary Learning – Create a shared learning environment for clinicians, researchers, policymakers, and community leaders to engage collaboratively around the future of psychedelic medicine.